Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
DAWN Price/Volume Stats
| Current price | $14.97 | 52-week high | $17.85 |
| Prev. close | $13.21 | 52-week low | $9.67 |
| Day low | $13.23 | Volume | 2,638,427 |
| Day high | $15.06 | Avg. volume | 832,016 |
| 50-day MA | $15.20 | Dividend yield | N/A |
| 200-day MA | $13.56 | Market Cap | 1.31B |
DAWN Stock Price Chart Interactive Chart >
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Latest DAWN News From Around the Web
Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.
Day One to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live |
Milei to Send ‘Shock’ Package to Argentina’s Congress on Day One(Bloomberg) -- President-elect Javier Milei plans to call congress into an extraordinary session and send a large package of reforms to stabilize Argentina’s economy on Dec. 11, the day after his inauguration.Most Read from BloombergBillions Wiped Out as Stock-Safety Trade on Wall Street MisfiresRussia Downs Drones Over Moscow in Ukrainian Retaliatory StrikeTreasuries Extend Blockbuster Rally on Fed Wagers: Markets WrapMusk, Netanyahu Visit Massacre Site Amid Antisemitism FurorIsrael, Hamas Exte |
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature MedicineData subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the publication of the registrational Phase 2 FIREFLY-1 trial results evaluating the |
Day One to Participate in the Piper Sandler 35th Annual Healthcare ConferenceBRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 at 11:30 a.m. EST. A live audio webcast of the discussion will be av |
Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate ProgressDAWN's Q3 2023 financial results reveal a net loss of $46.2 million and cash position of $405.5 million |
DAWN Price Returns
| 1-mo | -5.19% |
| 3-mo | 5.35% |
| 6-mo | 47.20% |
| 1-year | 23.72% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 2.53% |
| 2023 | -32.16% |
| 2022 | 27.72% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...